Anavex Life Sciences (NASDAQ:AVXL) Issues Earnings Results

Anavex Life Sciences (NASDAQ:AVXL) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, Yahoo Finance reports. During the same period last year, the company posted ($0.14) EPS.

Anavex Life Sciences Stock Down 0.8 %

NASDAQ AVXL traded down $0.05 during trading on Friday, hitting $6.59. The company’s stock had a trading volume of 27,501 shares, compared to its average volume of 1,318,052. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $10.45. The firm has a market cap of $557.79 million, a P/E ratio of -13.28 and a beta of 0.63. The firm has a 50 day moving average price of $4.97 and a 200 day moving average price of $4.87.

Analysts Set New Price Targets

Several analysts recently issued reports on AVXL shares. EF Hutton Acquisition Co. I raised shares of Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a report on Thursday, August 1st.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.